Find Naquotinib manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

0

USDMF

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

NDC API

0

VMF

0

Listed Suppliers

0INTERMEDIATES

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

FINISHED DOSAGE FORMULATIONS

0

FDF Dossiers

0

FDA Orange Book

0

Europe

0

Canada

0

Australia

0

South Africa

0

Listed Dossiers

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

PATENTS & EXCLUSIVITIES

0

US Patents

0

US Exclusivities

0

Health Canada Patents

API/FDF Prices: Book a Demo

API REF. PRICE (USD/KG)

$
$ 0

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Regulatory FDF Prices

NA

MARKET PLACE

0

API

0

FDF

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

0

News #PharmaBuzz

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1448232-80-1, Asp8273, Naquotinib [usan], Asp-8273, 2-pyrazinecarboxamide, 6-ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3r)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-, 47dd4548pb
Molecular Formula
C30H42N8O3
Molecular Weight
562.7  g/mol
InChI Key
QKDCLUARMDUUKN-XMMPIXPASA-N
FDA UNII
47DD4548PB

Naquotinib
Naquotinib is an orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, ASP8273 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. ASP8273 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.
1 2D Structure

Naquotinib

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3R)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide
2.1.2 InChI
InChI=1S/C30H42N8O3/c1-4-25-30(41-24-12-15-38(20-24)26(39)5-2)34-29(27(33-25)28(31)40)32-21-6-8-22(9-7-21)36-13-10-23(11-14-36)37-18-16-35(3)17-19-37/h5-9,23-24H,2,4,10-20H2,1,3H3,(H2,31,40)(H,32,34)/t24-/m1/s1
2.1.3 InChI Key
QKDCLUARMDUUKN-XMMPIXPASA-N
2.1.4 Canonical SMILES
CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC5CCN(C5)C(=O)C=C
2.1.5 Isomeric SMILES
CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)O[C@@H]5CCN(C5)C(=O)C=C
2.2 Other Identifiers
2.2.1 UNII
47DD4548PB
2.3 Synonyms
2.3.1 MeSH Synonyms

1. Asp-8273

2. Asp8273

2.3.2 Depositor-Supplied Synonyms

1. 1448232-80-1

2. Asp8273

3. Naquotinib [usan]

4. Asp-8273

5. 2-pyrazinecarboxamide, 6-ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3r)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-

6. 47dd4548pb

7. 6-ethyl-3-[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-[(3r)-1-prop-2-enoylpyrrolidin-3-yl]oxypyrazine-2-carboxamide

8. (r)-5-((1-acryloylpyrrolidin-3-yl)oxy)-6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrazine-2-carboxamide

9. 2-pyrazinecarboxamide, 6-ethyl-3-((4-(4-(4-methyl-1-piperazinyl)-1-piperidinyl)phenyl)amino)-5-(((3r)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl)oxy)-

10. E-2-carboxamide

11. Naquotinib [inn]

12. Naquotinib (usan/inn)

13. Asp8273 (naquotinib)

14. Naquotinib; Asp-8273

15. Naquotinib [who-dd]

16. Unii-47dd4548pb

17. Gtpl9248

18. Chembl3663929

19. Schembl16196078

20. Bdbm170514

21. Ex-a2669

22. Yhc23280

23. Nsc793322

24. S8412

25. Zinc205341959

26. Ccg-270060

27. Cs-5469

28. Db12036

29. Nsc-793322

30. Ac-35709

31. As-75247

32. Hy-19729

33. J3.496.214f

34. A14408

35. C91356

36. D10958

37. Us9085540, 54

38. A857977

39. Q27074546

40. 5-[[(3r)-1-acryloylpyrrolidine-3-yl]oxy]-6-ethyl-3-[4-[4-(4-methylpiperazine-1-yl)piperidino]anilino]pyrazine-2-carboxamide

41. 6-ethyl-3-((4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)phenyl)amino)-5-(((3r)-1-(1-oxoprop-2-en-1-yl)pyrrolidin-3-yl)oxy)pyrazine-2-carboxamide

42. 6-ethyl-3-({4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl}amino)-5-{[(3r)-1-(prop-2-enoyl)pyrrolidin-3-yl]oxy}pyrazine-2-carboxamide

43. 6-ethyl-3-(4-(4-(4-methylpiperazin-1-yl)piperidin- 1-yl)anilino)-5-(((3r)-1-(prop-2-enoyl)pyrrolidin- 3-yl)oxy)pyrazine-2-carboxamide

44. 6-ethyl-3-(4-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)anilino)-5-(((3r)-1-(prop-2-enoyl)pyrrolidin-3-yl)oxy)pyrazine-2-carboxamide

45. 6-ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3r)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-2-pyrazinecarboxamide

46. 6-ethyl-3-[[4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]phenyl]amino]-5-[(3r)-1-prop-2-enoylpyrrolidin-3-yl]oxy-pyrazin

2.4 Create Date
2013-09-02
3 Chemical and Physical Properties
Molecular Weight 562.7 g/mol
Molecular Formula C30H42N8O3
XLogP33.4
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count9
Exact Mass562.33798723 g/mol
Monoisotopic Mass562.33798723 g/mol
Topological Polar Surface Area120 Ų
Heavy Atom Count41
Formal Charge0
Complexity883
Isotope Atom Count0
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Pharmacology and Biochemistry
4.1 MeSH Pharmacological Classification

Antineoplastic Agents

Substances that inhibit or prevent the proliferation of NEOPLASMS. (See all compounds classified as Antineoplastic Agents.)


Protein Kinase Inhibitors

Agents that inhibit PROTEIN KINASES. (See all compounds classified as Protein Kinase Inhibitors.)


ABOUT THIS PAGE

Looking for 1448232-80-1 / Naquotinib API manufacturers, exporters & distributors?

Naquotinib manufacturers, exporters & distributors 1

40

PharmaCompass offers a list of Naquotinib API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Naquotinib manufacturer or Naquotinib supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Naquotinib manufacturer or Naquotinib supplier.

PharmaCompass also assists you with knowing the Naquotinib API Price utilized in the formulation of products. Naquotinib API Price is not always fixed or binding as the Naquotinib Price is obtained through a variety of data sources. The Naquotinib Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.

API | Excipient name

Naquotinib

Synonyms

1448232-80-1, Asp8273, Naquotinib [usan], Asp-8273, 2-pyrazinecarboxamide, 6-ethyl-3-[[4-[4-(4-methyl-1-piperazinyl)-1-piperidinyl]phenyl]amino]-5-[[(3r)-1-(1-oxo-2-propen-1-yl)-3-pyrrolidinyl]oxy]-, 47dd4548pb

Cas Number

1448232-80-1

Unique Ingredient Identifier (UNII)

47DD4548PB

About Naquotinib

Naquotinib is an orally available, irreversible, third-generation, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential antineoplastic activity. Upon oral administration, ASP8273 covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M EGFR mutant, thereby preventing EGFR-mediated signaling. This may both induce cell death and inhibit tumor growth in EGFR-overexpressing tumor cells. EGFR, a receptor tyrosine kinase mutated in many tumor cell types, plays a key role in tumor cell proliferation and tumor vascularization. ASP8273 preferentially inhibits mutated forms of EGFR including T790M, a secondarily acquired resistance mutation, and may have therapeutic benefits in tumors with T790M-mediated resistance when compared to other EGFR tyrosine kinase inhibitors. As this agent is selective towards mutant forms of EGFR, its toxicity profile may be reduced as compared to non-selective EGFR inhibitors which also inhibit wild-type EGFR.

Naquotinib Manufacturers

A Naquotinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Naquotinib, including repackagers and relabelers. The FDA regulates Naquotinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Naquotinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Naquotinib Suppliers

A Naquotinib supplier is an individual or a company that provides Naquotinib active pharmaceutical ingredient (API) or Naquotinib finished formulations upon request. The Naquotinib suppliers may include Naquotinib API manufacturers, exporters, distributors and traders.

Naquotinib GMP

Naquotinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Naquotinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Naquotinib GMP manufacturer or Naquotinib GMP API supplier for your needs.

Naquotinib CoA

A Naquotinib CoA (Certificate of Analysis) is a formal document that attests to Naquotinib's compliance with Naquotinib specifications and serves as a tool for batch-level quality control.

Naquotinib CoA mostly includes findings from lab analyses of a specific batch. For each Naquotinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Naquotinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Naquotinib EP), Naquotinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Naquotinib USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty